Development of TNBS-induced colitis: animal model to test new pharmacological approaches

Detalhes bibliográficos
Autor(a) principal: Mateus, V.
Data de Publicação: 2013
Outros Autores: Faísca, P., Mota-Filipe, H., Sepodes, Bruno M., Pinto, R.
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/4
Resumo: IBD is a gastro-intestinal disorder marked with chronic inflammation of intestinal epithelium, dam- aging mucosal tissue and manifests into several intestinal and extra-intestinal symptoms. Currently used medical therapy is able to induce and maintain the patient in remission, however no modifies or reverses the underlying pathogenic mechanism. The research of other medical approaches is crucial to the treatment of IBD and, for this, it ́s important to use animal models to mimic the characteristics of disease in real life. The aim of the study is to develop an animal model of TNBS-induced colitis to test new pharmacological approaches. TNBS was instilled intracolonic single dose as described by Morris et al. It was administered 2,5% TNBS in 50% ethanol through a catheter carefully inserted into the colon. Mice were kept in a Tredelenburg position to avoid reflux. On day 4 and 7, the animals were sacrificed by cervical dislocation. The induction was confirmed based on clinical symptoms/signs, ALP determination and histopathological analysis. At day 4, TNBS group presented a decreased body weight and an alteration of intestinal motility characterized by diarrhea, severe edema of the anus and moderate morbidity, while in the two control groups weren’t identified any alteration on the clinical symptoms/signs with an increase of the body weight. TNBS group presented the highest concentrations of ALP comparing with control groups. The histopathology analysis revealed severe necrosis of the mucosa with widespread necrosis of the intestinal glands. Severe hemorrhagic and purulent exsudates were observed in the submucosa, muscular and serosa. TNBS group presented clinical symptoms/ signs and histopathological features compatible with a correct induction of UC. The peak of manifestations became maximal at day 4 after induction. This study allows concluding that it’s possible to develop a TNBS- induced colitis 4 days after instillation. 
id RCAP_eff676874e8d49c12ff7ebd0ff25565b
oai_identifier_str oai:ojs.actafarmaceuticaportuguesa.com:article/4
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Development of TNBS-induced colitis: animal model to test new pharmacological approachesDevelopment of TNBS-induced colitis: animal model to test new pharmacological approachesIBDTNBS-induced colitisInflammationMetabolic pathwaysPharmacological targetsDIIColite induzida por TNBSInflamaçãoVias metabólicasAlvos farmacológicos.IBD is a gastro-intestinal disorder marked with chronic inflammation of intestinal epithelium, dam- aging mucosal tissue and manifests into several intestinal and extra-intestinal symptoms. Currently used medical therapy is able to induce and maintain the patient in remission, however no modifies or reverses the underlying pathogenic mechanism. The research of other medical approaches is crucial to the treatment of IBD and, for this, it ́s important to use animal models to mimic the characteristics of disease in real life. The aim of the study is to develop an animal model of TNBS-induced colitis to test new pharmacological approaches. TNBS was instilled intracolonic single dose as described by Morris et al. It was administered 2,5% TNBS in 50% ethanol through a catheter carefully inserted into the colon. Mice were kept in a Tredelenburg position to avoid reflux. On day 4 and 7, the animals were sacrificed by cervical dislocation. The induction was confirmed based on clinical symptoms/signs, ALP determination and histopathological analysis. At day 4, TNBS group presented a decreased body weight and an alteration of intestinal motility characterized by diarrhea, severe edema of the anus and moderate morbidity, while in the two control groups weren’t identified any alteration on the clinical symptoms/signs with an increase of the body weight. TNBS group presented the highest concentrations of ALP comparing with control groups. The histopathology analysis revealed severe necrosis of the mucosa with widespread necrosis of the intestinal glands. Severe hemorrhagic and purulent exsudates were observed in the submucosa, muscular and serosa. TNBS group presented clinical symptoms/ signs and histopathological features compatible with a correct induction of UC. The peak of manifestations became maximal at day 4 after induction. This study allows concluding that it’s possible to develop a TNBS- induced colitis 4 days after instillation. DII é um distúrbio gastro-intestinal caracterizado por inflamação crónica do epitélio intestinal com dano associado da mucosa, manifestando-se a partir de sintomas intestinais e extra-intestinais. A terapia médica utilizada é capaz de induzir e manter o doente em remissão, mas não modifica ou inverte o mecanismo patogénico subjacente. A procura de outras abordagens terapêuticas é crucial para o tratamento de DII e, para tal, é importante o uso de modelos animais para mimetizar as características da doença. O objetivo do estudo é desenvolver um modelo animal de colite induzida por TNBS de modo a testar novas abordagens farmacológicas. O TNBS foi instilado por via intracolónica em dose única como descrito por Morris et al. Foi administrado 2,5% de TNBS em 50% de etanol através de um cateter inserido no cólon. Os animais foram mantidos em posição Tredelenburg para evitar o refluxo. Nos dias 4 e 7, os animais foram sacrificados por deslocamento cervical. A indução de colite foi caracterizada com base nos sintomas/sinais clínicos, determinação de ALP e análise histopatológica. No dia 4, o grupo TNBS apresentou uma diminuição do peso corporal e uma alteração da motilidade intestinal caracterizada por diarreia, edema severo do ânus e morbilidade moderada, enquanto nos dois grupos controlo não foram identificados quaisquer alterações nos sintomas/ sinais clínicos com um aumento do peso corporal. O grupo TNBS apresentou as maiores concentrações de ALP, comparando com os grupos controlo. A análise histopatológica demonstrou necrose grave da mucosa com necrose generalizada das glândulas intestinais. Foi observado exsudato hemorrágico e purulento ao nível da submucosa, muscular e serosa. O grupo TNBS apresentou sintomas / sinais clínicos e características histopatológicas compatíveis com uma correta indução de colite. O pico das manifestações tornou-se máximo ao 4º dia após a indução. Este estudo permite concluir que é possível desenvolver colite induzida por TNBS 4 dias após a instilação. Acta Farmacêutica Portuguesa2013-12-20T00:00:00Zjournal articleinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://actafarmaceuticaportuguesa.com/index.php/afp/article/view/4oai:ojs.actafarmaceuticaportuguesa.com:article/4Acta Farmacêutica Portuguesa; v. 2 n. 2 (2013); 29-352182-3340reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://actafarmaceuticaportuguesa.com/index.php/afp/article/view/4https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/4/104Mateus, V.Faísca, P.Mota-Filipe, H.Sepodes, Bruno M.Pinto, R.info:eu-repo/semantics/openAccess2022-09-05T12:29:43Zoai:ojs.actafarmaceuticaportuguesa.com:article/4Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T14:59:51.344960Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Development of TNBS-induced colitis: animal model to test new pharmacological approaches
Development of TNBS-induced colitis: animal model to test new pharmacological approaches
title Development of TNBS-induced colitis: animal model to test new pharmacological approaches
spellingShingle Development of TNBS-induced colitis: animal model to test new pharmacological approaches
Mateus, V.
IBD
TNBS-induced colitis
Inflammation
Metabolic pathways
Pharmacological targets
DII
Colite induzida por TNBS
Inflamação
Vias metabólicas
Alvos farmacológicos.
title_short Development of TNBS-induced colitis: animal model to test new pharmacological approaches
title_full Development of TNBS-induced colitis: animal model to test new pharmacological approaches
title_fullStr Development of TNBS-induced colitis: animal model to test new pharmacological approaches
title_full_unstemmed Development of TNBS-induced colitis: animal model to test new pharmacological approaches
title_sort Development of TNBS-induced colitis: animal model to test new pharmacological approaches
author Mateus, V.
author_facet Mateus, V.
Faísca, P.
Mota-Filipe, H.
Sepodes, Bruno M.
Pinto, R.
author_role author
author2 Faísca, P.
Mota-Filipe, H.
Sepodes, Bruno M.
Pinto, R.
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Mateus, V.
Faísca, P.
Mota-Filipe, H.
Sepodes, Bruno M.
Pinto, R.
dc.subject.por.fl_str_mv IBD
TNBS-induced colitis
Inflammation
Metabolic pathways
Pharmacological targets
DII
Colite induzida por TNBS
Inflamação
Vias metabólicas
Alvos farmacológicos.
topic IBD
TNBS-induced colitis
Inflammation
Metabolic pathways
Pharmacological targets
DII
Colite induzida por TNBS
Inflamação
Vias metabólicas
Alvos farmacológicos.
description IBD is a gastro-intestinal disorder marked with chronic inflammation of intestinal epithelium, dam- aging mucosal tissue and manifests into several intestinal and extra-intestinal symptoms. Currently used medical therapy is able to induce and maintain the patient in remission, however no modifies or reverses the underlying pathogenic mechanism. The research of other medical approaches is crucial to the treatment of IBD and, for this, it ́s important to use animal models to mimic the characteristics of disease in real life. The aim of the study is to develop an animal model of TNBS-induced colitis to test new pharmacological approaches. TNBS was instilled intracolonic single dose as described by Morris et al. It was administered 2,5% TNBS in 50% ethanol through a catheter carefully inserted into the colon. Mice were kept in a Tredelenburg position to avoid reflux. On day 4 and 7, the animals were sacrificed by cervical dislocation. The induction was confirmed based on clinical symptoms/signs, ALP determination and histopathological analysis. At day 4, TNBS group presented a decreased body weight and an alteration of intestinal motility characterized by diarrhea, severe edema of the anus and moderate morbidity, while in the two control groups weren’t identified any alteration on the clinical symptoms/signs with an increase of the body weight. TNBS group presented the highest concentrations of ALP comparing with control groups. The histopathology analysis revealed severe necrosis of the mucosa with widespread necrosis of the intestinal glands. Severe hemorrhagic and purulent exsudates were observed in the submucosa, muscular and serosa. TNBS group presented clinical symptoms/ signs and histopathological features compatible with a correct induction of UC. The peak of manifestations became maximal at day 4 after induction. This study allows concluding that it’s possible to develop a TNBS- induced colitis 4 days after instillation. 
publishDate 2013
dc.date.none.fl_str_mv 2013-12-20T00:00:00Z
dc.type.driver.fl_str_mv journal article
info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/4
oai:ojs.actafarmaceuticaportuguesa.com:article/4
url https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/4
identifier_str_mv oai:ojs.actafarmaceuticaportuguesa.com:article/4
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/4
https://actafarmaceuticaportuguesa.com/index.php/afp/article/view/4/104
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Acta Farmacêutica Portuguesa
publisher.none.fl_str_mv Acta Farmacêutica Portuguesa
dc.source.none.fl_str_mv Acta Farmacêutica Portuguesa; v. 2 n. 2 (2013); 29-35
2182-3340
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799129870944436224